Major Estimate Revision • May 24
Consensus revenue estimates fall by 64% The consensus outlook for revenues in fiscal year 2026 has deteriorated. 2026 revenue forecast decreased from kr44.0m to kr16.0m. Forecast losses increased from -kr0.23 to -kr0.24 per share. Biotechs industry in Sweden expected to see average net income growth of 22% next year. Consensus price target of kr2.10 unchanged from last update. Share price rose 12% to kr1.27 over the past week. Major Estimate Revision • May 20
Consensus revenue estimates decrease by 63%, EPS upgraded The consensus outlook for fiscal year 2026 has been updated. 2026 revenue forecast fell from kr44.0m to kr16.2m. EPS estimate increased from -kr0.23 to -kr0.22 per share. Biotechs industry in Sweden expected to see average net income growth of 13% next year. Consensus price target down from kr2.20 to kr2.10. Share price rose 5.3% to kr1.20 over the past week. Price Target Changed • May 15
Price target decreased by 11% to kr2.10 Down from kr2.35, the current price target is provided by 1 analyst. New target price is 86% above last closing price of kr1.13. Stock is down 4.2% over the past year. The company is forecast to post a net loss per share of kr0.22 next year compared to a net loss per share of kr0.27 last year. Aankondiging • May 15
Intervacc AB (Publ) Appoints Emil Billbäck as Chairperson Intervacc AB (publ) held its Annual General Meeting on 13 May 2026, and Emil Billbäck was elected as the Board of Directors' new chairperson for the period up to and including the next AGM. Reported Earnings • May 15
First quarter 2026 earnings: EPS in line with expectations, revenues disappoint First quarter 2026 results: kr0.06 loss per share. Net loss: kr21.7m (loss widened 65% from 1Q 2025). Revenue is forecast to grow 74% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Biotechs industry in Sweden. Aankondiging • May 13
Intervacc AB Announces Appointment of Lars Stubberud as Chief Technology Officer, Effective July 15, 2026 Intervacc AB (publ) announced the recruitment of Lars Stubberud as Chief Technology Officer (CTO), effective July 15, 2026. Lars Stubberud, M.Sc. Pharm, Ph.D., has more than 30 years' experience from the pharmaceutical industry, with responsibilities and expertise spanning broad CMC, product development, formulation, technology transfer, supply chain management, quality control and CMC regulatory affairs. He most recently held the position of Vice President Quality Assurance, Quality Control/Analytical Development at Calliditas Therapeutics AB, Stockholm, Sweden. The management team also comprises Jan Persson, CFO, Anna-Carin Lagerlöf, Head of Sales and Marketing, and Andrew Waller, Chief Scientific Officer. Aankondiging • Apr 18
Intervacc AB Announces Approval and Launch of Strangvac Vaccine in Iceland Intervacc AB (publ) announced that Strangvac, the company's innovative vaccine against strangles in horses, has been approved by the authorities in Iceland. Strangles, a potentially lethal infection caused by Streptococcus equi, is the most frequently diagnosed infectious disease of horses worldwide. However, it has not been permitted to import horses into Iceland for over 1,000 years and so this country retains the only strangles-free horse population in the world. Whilst horses within Iceland do not develop strangles, they have no natural immunity and are highly susceptible to this disease should they come into contact with S. equi. This has been a longstanding issue for horses exported from Iceland to other parts of the world. Strangvac is the only vaccine against strangles that generates a protective immune response, whilst still permitting the diagnosis of horses that have been exposed to, or are infected with, S. equi. This unique feature enables continued disease surveillance to provide evidence in support of Iceland's disease-free status and the protection of exported horses, which is important for Iceland's veterinarians and horse breeders, as well as the new owners. This approval is particularly noteworthy as the vaccination of horses to protect against infectious diseases is generally prohibited in Iceland, making the decision both unique and highly significant. Reported Earnings • Apr 15
Full year 2025 earnings: EPS exceeds analyst expectations while revenues lag behind Full year 2025 results: kr0.27 loss per share. Net loss: kr80.8m (loss widened 7.0% from FY 2024). Revenue missed analyst estimates by 20%. Earnings per share (EPS) exceeded analyst estimates by 13%. Revenue is forecast to grow 67% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Biotechs industry in Sweden. Aankondiging • Mar 20
Intervacc AB Publ Announces Breakthrough Protection Against Streptococcus Suis Infection in Piglets Intervacc AB (publ) is first in the world to show that piglets were protected against the virulent and severe disease-causing S. suis Sequence Types 1 and 16 (serotype 2 and 9, respectively), by vaccinating sows and transferring maternal immunity to piglets. The protection was proven in two separate challenge studies. Streptococcus suis is an important worldwide endemic swine pathogen, which causes meningitis, septicemia, arthritis, and endocarditis in weaned piglets between 4 and 10 weeks of age. Mortality rates can be as high as 20% in some farms and the total cost of S. suis infection in pigs is estimated to more than EUR 250 million annually in Europe alone. As of today, there are no approved vaccines available against S. suis infection in pigs. The experimental infection model involved the intravenous administration of a high dose of the virulent serotype 9 strain of S. suis (ST16) to induce systemic disease. The study showed that vaccination of pregnant sows was safe and provided statistically significant protection (total clinical score; p = 0.017) to piglets compared with piglets from an unvaccinated control group. The vaccine has previously conferred statistically significant protection to piglets against a virulent serotype 2 strain (ST1). The vaccine is administered to pregnant sows by intramuscular injection making it simple and cost-effective for pig farmers to use. The subunit vaccine, which is based on Intervacc's platform using recombinant fusion proteins, is designed to give protection against a wide range of S. suis strain types, using conserved, immunogenic, and virulence-associated proteins from S. suis. S. suis serotype 2 strains are the most common global cause of severe disease in piglets. Serotype 9 is currently less prevalent than serotype 2 but is increasingly responsible for severe pig diseases in Europe. Protection from a vaccine against multiple S. suis serotypes has been sought after by the pig farming industry for many years. Intervacc is the first company to show that a vaccine protected piglets against the highly virulent serotypes 2 (ST1) and 9 (ST16). This is a major breakthrough since the strains used in the studies are not closely related and the vaccine was only administered to pregnant sows with subsequent transfer of maternal immunity to their piglets. It is estimated that S. suis accounts for one-third of the total antibiotic usage in weaner pigs. A safe and efficacious vaccine against S. suis would reduce the need for antibiotics and the global threat from antimicrobial resistance, play a significant role in improving animal welfare, and improve the profitability of the pig farming industry. Intervacc will continue advancing the vaccine and prepare for GMP manufacturing and pivotal clinical studies. Major Estimate Revision • Feb 24
Consensus revenue estimates decrease by 13% The consensus outlook for fiscal year 2026 has been updated. 2026 revenue forecast fell from kr51.0m to kr44.3m. EPS estimate unchanged from -kr0.23 per share at last update. Biotechs industry in Sweden expected to see average net income growth of 11% next year. Consensus price target down from kr2.35 to kr2.20. Share price fell 9.6% to kr0.64 over the past week. Reported Earnings • Feb 18
Full year 2025 earnings: EPS exceeds analyst expectations while revenues lag behind Full year 2025 results: kr0.27 loss per share. Net loss: kr80.8m (loss widened 7.0% from FY 2024). Revenue missed analyst estimates by 20%. Earnings per share (EPS) exceeded analyst estimates by 13%. Revenue is forecast to grow 66% p.a. on average during the next 3 years, compared to a 8.1% growth forecast for the Biotechs industry in Sweden. Aankondiging • Feb 18
Intervacc AB (publ), Annual General Meeting, May 13, 2026 Intervacc AB (publ), Annual General Meeting, May 13, 2026. New Risk • Feb 17
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Swedish stocks, typically moving 9.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (350% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (kr26m net loss in 3 years). Share price has been volatile over the past 3 months (9.3% average weekly change). Revenue is less than US$5m (kr21m revenue, or US$2.3m). Market cap is less than US$100m (kr242.0m market cap, or US$26.9m). Aankondiging • Feb 06
Intervacc AB Announces Chief Executive Officer Changes The Board of Directors of Intervacc AB (publ), together with Jonas Sohlman, has agreed that will leave his role as Chief Executive Officer and Group CEO. Simultaneously, the Board has appointed Carl-Johan Dalsgaard as the new Chief Executive Officer and Group CEO with immediate effect. Carl-Johan Dalsgaard has an extensive clinical and scientific background, is a specialist physician, and holds a PhD from the Karolinska Institute. He has more than 25 years of experience in drug development at Astra/AstraZeneca and several biotech companies. Since 2000, Carl-Johan has been active as a Venture Partner at HealthCap, a leading European life science venture capital investor. He has served as CEO of several biotechnology companies, including Vicore Pharma (publ), Biolipox and Affibody. Carl-Johan also has many years of board experience, including Renovo (UK, public) and Tengion (US, public). Reported Earnings • Nov 20
Third quarter 2025 earnings released: kr0.04 loss per share (vs kr0.29 loss in 3Q 2024) Third quarter 2025 results: kr0.04 loss per share (improved from kr0.29 loss in 3Q 2024). Net loss: kr14.3m (loss narrowed 36% from 3Q 2024). Revenue is forecast to grow 59% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Biotechs industry in Sweden. Aankondiging • Sep 27
Intervacc Appoints Anna-Carin Lagerlöf as Sales and Marketing Director The animal health group Intervacc AB (publ) has appointed Anna-Carin Lagerlöf to the newly established role as Sales and Marketing Director. In this position, Anna-Carin will lead the company's continued sales growth, with a particular focus on Strangvac - Intervacc's vaccine against strangles, a common infectious disease in horses. Anna-Carin brings extensive experience from the animal health market and joins Intervacc from IDEXX Laboratories, where she served as Country Manager for the Nordics. She will assume her new role in November and will also become a member of the company's executive management team. Reported Earnings • Aug 31
Second quarter 2025 earnings released: kr0.05 loss per share (vs kr0.24 loss in 2Q 2024) Second quarter 2025 results: kr0.05 loss per share (improved from kr0.24 loss in 2Q 2024). Net loss: kr17.8m (flat on 2Q 2024). Revenue is forecast to grow 57% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Biotechs industry in Sweden. Aankondiging • Aug 19
Dechra Pharmaceuticals PLC Launches Strangvac in Spain, Portugal and Slovenia Intervacc AB (publ) announced that its European distribution partner, Dechra Pharmaceuticals PLC, is launching Strangvac in Spain, Portugal and Slovenia. Vials of the vaccine against the highly contagious bacterial equine disease strangles are expected to be available for delivery in these markets shortly. New Risk • May 19
New major risk - Revenue and earnings growth Earnings have declined by 29% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 29% per year over the past 5 years. Shareholders have been substantially diluted in the past year (350% increase in shares outstanding). Minor Risks Revenue is less than US$5m (kr15m revenue, or US$1.5m). Market cap is less than US$100m (kr402.8m market cap, or US$41.6m). Reported Earnings • May 15
First quarter 2025 earnings: EPS and revenues exceed analyst expectations First quarter 2025 results: kr0.08 loss per share (improved from kr0.23 loss in 1Q 2024). Net loss: kr13.2m (loss narrowed 24% from 1Q 2024). Revenue exceeded analyst estimates by 12%. Earnings per share (EPS) also surpassed analyst estimates by 64%. Revenue is forecast to grow 106% p.a. on average during the next 2 years, compared to a 16% growth forecast for the Biotechs industry in Sweden. Aankondiging • Mar 29
Veterinary Medicines Directorate Approves Intervacc's Variation Application Intervacc AB (publ) announced that the variation application previously submitted to the U.K's Veterinary Medicines Directorate, (VMD), has now been approved. The approval concerns improved methods and processes which are a part of the manufacturing process for Strangvac®, the company's vaccine against equine strangles. As previously announced, the EMA has approved the corresponding variation application, and together these two approvals mark an important milestone in Intervacc's efforts to ensure increased flexibility and stability in production processes. The improved processes have already been implemented in the production carried out during the autumn, and new vials has been made available for sale through a special procedure, Special Batch Release, in markets where it has been launched. New Risk • Mar 13
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 350% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Shareholders have been substantially diluted in the past year (350% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (kr38m net loss in 2 years). Revenue is less than US$5m (kr12m revenue, or US$1.2m). Market cap is less than US$100m (kr327.2m market cap, or US$32.5m). Reported Earnings • Feb 14
Full year 2024 earnings: EPS in line with expectations, revenues disappoint Full year 2024 results: kr1.00 loss per share (improved from kr1.59 loss in FY 2023). Net loss: kr75.5m (loss narrowed 27% from FY 2023). Revenue is forecast to grow 94% p.a. on average during the next 2 years, compared to a 20% growth forecast for the Biotechs industry in Sweden. New Risk • Feb 13
New major risk - Revenue and earnings growth Earnings have declined by 35% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (20% average weekly change). Earnings have declined by 35% per year over the past 5 years. Revenue is less than US$1m (kr9.3m revenue, or US$856k). Market cap is less than US$10m (kr68.2m market cap, or US$6.28m). Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (kr38m net loss in 2 years). Aankondiging • Dec 25
Intervacc AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 225.315385 million. Intervacc AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 225.315385 million.
Security Name: Shares
Security Type: Common Stock
Securities Offered: 265,076,924
Price\Range: SEK 0.85
Transaction Features: Rights Offering New Risk • Dec 19
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr49m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Revenue is less than US$1m (kr9.3m revenue, or US$841k). Market cap is less than US$10m (kr91.6m market cap, or US$8.30m). Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (kr45m net loss in 2 years). Reported Earnings • Nov 15
Third quarter 2024 earnings released: kr0.29 loss per share (vs kr0.63 loss in 3Q 2023) Third quarter 2024 results: kr0.29 loss per share (improved from kr0.63 loss in 3Q 2023). Net loss: kr22.2m (loss narrowed 53% from 3Q 2023). Revenue is forecast to grow 97% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in Sweden. Reported Earnings • Aug 30
Second quarter 2024 earnings released: kr0.24 loss per share (vs kr0.32 loss in 2Q 2023) Second quarter 2024 results: kr0.24 loss per share (improved from kr0.32 loss in 2Q 2023). Net loss: kr17.8m (flat on 2Q 2023). Revenue is forecast to grow 85% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Biotechs industry in Sweden. Reported Earnings • May 16
First quarter 2024 earnings released: kr0.23 loss per share (vs kr0.35 loss in 1Q 2023) First quarter 2024 results: kr0.23 loss per share (improved from kr0.35 loss in 1Q 2023). Net loss: kr17.4m (flat on 1Q 2023). Revenue is forecast to grow 84% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 42% per year but the company’s share price has fallen by 62% per year, which means it is performing significantly worse than earnings. Aankondiging • May 16
Intervacc AB (Publ) Announces Board Appointments Intervacc AB (publ) announced at the AGM held on May 15, 2024, approved to elect Mathias Uhlen and Emil Billbäck, as Board members for the period up to and including the next AGM. Aankondiging • Mar 05
Intervacc AB (publ) Announces Changes in the Nomination Committee Intervacc AB (publ) announced that the composition of the Nomination Committee in the company was announced in a Press Release on October 30, 2023. Due to the fact that Ulrika Enhörning, appointed by Swedbank Robur Fonder and Thomas Ehlin, appointed by Fjärde AP-fonden in December 2023 announced that they had chosen to resign from their assignment in the Nomination Committee, new members have been appointed to the Nomination Committee in accordance with the principles for appointing the Nomination Committee in Intervacc that were adopted at the Annual General Meeting on June 14, 2022. After the changes, the Nomination Committee in Intervacc before 2024 Annual General Meeting has the following composition: Magnus Lundberg, appointed by ownership group consisting of Håkan Björklund and Magnus Lundberg Christian Rudbäck, appointed by ownership group consisting of Jan-Ingmar Flock, NR Bergman Holding AB, Kenneth Janzon, Christian Rudbäck och Johan Virgin. Björn Sjöstrand, own possession. Aankondiging • Feb 28
Jonas Sohlman Appoints as New CEO for Intervacc AB (publ) Intervacc AB (publ) announced that acting CEO Jonas Sohlman has been appointed as the new CEO of Intervacc AB and assumes the position immediately. The recruitment process that the previous board initiated has continued and now resulted in the appointment of Jonas Sohlman as the new CEO. Jonas has been working as the acting CEO since last August and assumes the role of CEO starting Feb. 28, 2024. Jonas Sohlman has extensive experience from leadership positions in publicly listed companies. He most recently held the role of CFO at Enorama Pharma. Additionally, he has solid experience within the equestrian industry and currently serves as the chairman of both Flyinge AB and Ridskolan Strömsholm AB. Reported Earnings • Feb 18
Full year 2023 earnings: EPS and revenues miss analyst expectations Full year 2023 results: kr1.69 loss per share (further deteriorated from kr1.28 loss in FY 2022). Net loss: kr102.9m (loss widened 60% from FY 2022). Revenue missed analyst estimates by 47%. Earnings per share (EPS) also missed analyst estimates by 48%. Revenue is forecast to grow 113% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Biotechs industry in Sweden. Aankondiging • Dec 21
Intervacc AB (publ) Announces Changes in the Nomination Committee Intervacc AB (publ) announced that the company and the chairman of the board have been informed that Ulrika Enhörning, appointed by Swedbank Robur Fonder and Thomas Ehlin, appointed by Fjärde AP-fonden have resigned from the Nomination Committee. Board Change • Nov 29
No independent directors There are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). Director Camilla McCarthy is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors. Aankondiging • Nov 24
Intervacc AB (publ) Announces Executive Changes Intervacc AB (publ) at its Extraordinary General Meeting held on 23 November 2023, resolved, in accordance with the shareholder group’s proposal, that the Board of Directors shall consist of five board members without deputies. Further, the EGM resolved, with the dismissal of all of the current board members, Björn Sjöstrand, Bengt Guss, Niels Holck, Stefan Ståhl, Boel Sundvall, Ed Torr and Michela de Carli, to, in accordance with the shareholder group’s proposal, elect Håkan Björklund, Jan-Ingmar Flock, Lisen Bratt Fredricson, Lennart Johansson and Camilla Ramfelt McCarthy, as new board members for the period until the end of the next Annual General Meeting. Håkan Björklund was elected chairperson of the Board of Directors. New Risk • Nov 18
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Revenue is less than US$1m (kr10m revenue, or US$977k). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (kr31m net loss in 2 years). Shareholders have been diluted in the past year (50% increase in shares outstanding). Significant insider selling over the past 3 months (kr3.4m sold). Market cap is less than US$100m (kr452.1m market cap, or US$42.8m). Reported Earnings • Nov 17
Third quarter 2023 earnings released: kr0.78 loss per share (vs kr0.29 loss in 3Q 2022) Third quarter 2023 results: kr0.78 loss per share (further deteriorated from kr0.29 loss in 3Q 2022). Net loss: kr47.5m (loss widened 225% from 3Q 2022). Revenue is forecast to grow 122% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 45% per year whereas the company’s share price has fallen by 48% per year. Aankondiging • Oct 31
Intervacc AB (publ) Announces Composition of Nomination Committee Intervacc AB (publ) announced the Nomination Committee consists of Ulrika Enhörning, appointed by Swedbank Robur Fonder; Thomas Ehlin, appointed by Fjärde AP-fonden and Magnus Lundberg, appointed by Håkan Björklund och Magnus Lundberg. Reported Earnings • Sep 01
Second quarter 2023 earnings released: kr0.34 loss per share (vs kr0.31 loss in 2Q 2022) Second quarter 2023 results: kr0.34 loss per share (further deteriorated from kr0.31 loss in 2Q 2022). Net loss: kr18.0m (loss widened 14% from 2Q 2022). Revenue is forecast to grow 103% p.a. on average during the next 3 years, compared to a 25% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 38% per year but the company’s share price has fallen by 49% per year, which means it is performing significantly worse than earnings. Aankondiging • Aug 18
Intervacc AB (publ) Receives Grant to Optimise Production Processes for A Fusion Protein from Vinnova Intervacc AB (publ) announced that it has been awarded an "industrial research" grant from Vinnova as part of a project with Testa Center, Uppsala, Sweden, to optimise the manufacturing processes of one component for a prototype vaccine for pigs. Intervacc's innovative technology utilises fusion proteins in vaccines to generate broad-acting immune responses that provide protection to animals from complex bacterial diseases. Streptococcus suis causes meningitis, sepsis and arthritis in young piglets, leading to significant costs to the pig industry throughout the world. Early proof-of-concept studies found that the consumption of colostrum from sows that were vaccinated with Intervacc's prototype vaccine against Streptococcus suis provided significant levels of protection to piglets at 4 and 7 weeks of age against challenge with a virulent strain of Streptococcus suis. Testa Center provide access to a lab environment with a modern, pilot-scale testbed to optimise the scale-up processes required to manufacture biologics. The new industrial research project provides a grant to Intervacc of 800, SEK funded by Vinnova, which corresponds to about 70% of the cost of this development phase at Testa Center. Aankondiging • Jun 09
Intervacc AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 103.506226 million. Intervacc AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 103.506226 million.
Security Name: Shares
Security Type: Common Stock
Securities Offered: 25,245,421
Price\Range: SEK 4.1
Transaction Features: Rights Offering Aankondiging • Jun 08
Intervacc AB (Publ) Approves the Election of Boel Sundvall as Board Member Intervacc AB (publ) has held its Annual General Meeting (”AGM”) on 7 June 2023. To elect Boel Sundvall, as Board members for the period up to and including the next AGM. Aankondiging • May 19
The European Medicines Agency Approves Extention of Shelf Life for Strangvac, Vaccine Against Equine Strangvac, to 33 Months The European Medicines Agency (EMA) has, after reviewing stability data, approved the extension of the shelf life for Strangvac, to 33 months from previously 24 months. The Veterinary Medicines Directorate (VMD) the authority responsible for veterinary medicines in the UK, has previously approved the extension of the shelves life for Strangvac. Aankondiging • May 10
Veterinary Medicines Directorate (VMD) Extends the Shelf Life for Intervacc AB (publ)'s Strangvac, a Vaccine Against Equine Strangvac, to 33 Months Intervacc AB (publ) announced that the Veterinary Medicines Directorate (VMD) has, after reviewing stability data, approved the extension of the shelf life for Strangvac, to 33 months from previously 24 months. Reported Earnings • May 04
First quarter 2023 earnings released: kr0.35 loss per share (vs kr0.21 loss in 1Q 2022) First quarter 2023 results: kr0.35 loss per share (further deteriorated from kr0.21 loss in 1Q 2022). Net loss: kr17.5m (loss widened 63% from 1Q 2022). Revenue is forecast to grow 51% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 30% per year whereas the company’s share price has fallen by 31% per year. Breakeven Date Change • Mar 30
Forecast breakeven date pushed back to 2025 The analyst covering Intervacc previously expected the company to break even in 2024. New forecast suggests losses will reduce by 40% per year to 2024. The company is expected to make a profit of kr24.0m in 2025. Average annual earnings growth of 70% is required to achieve expected profit on schedule. Reported Earnings • Feb 19
Full year 2022 earnings released: kr1.28 loss per share (vs kr0.59 loss in FY 2021) Full year 2022 results: kr1.28 loss per share (further deteriorated from kr0.59 loss in FY 2021). Net loss: kr64.2m (loss widened 118% from FY 2021). Revenue is forecast to grow 50% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 19% per year whereas the company’s share price has fallen by 15% per year. Breakeven Date Change • Jan 01
Forecast breakeven date pushed back to 2024 The 3 analysts covering Intervacc previously expected the company to break even in 2022. New consensus forecast suggests losses will reduce by 38% per year to 2023. The company is expected to make a profit of kr59.6m in 2024. Average annual earnings growth of 94% is required to achieve expected profit on schedule. Reported Earnings • Nov 16
Third quarter 2022 earnings released: kr0.29 loss per share (vs kr0.17 loss in 3Q 2021) Third quarter 2022 results: kr0.29 loss per share (further deteriorated from kr0.17 loss in 3Q 2021). Net loss: kr14.6m (loss widened 76% from 3Q 2021). Revenue is forecast to grow 61% p.a. on average during the next 3 years, compared to a 28% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has increased by 11% per year, which means it is well ahead of earnings. Reported Earnings • Nov 12
Third quarter 2022 earnings released: kr0.29 loss per share (vs kr0.17 loss in 3Q 2021) Third quarter 2022 results: kr0.29 loss per share (further deteriorated from kr0.17 loss in 3Q 2021). Net loss: kr14.6m (loss widened 76% from 3Q 2021). Revenue is forecast to grow 61% p.a. on average during the next 3 years, compared to a 27% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings. Reported Earnings • Sep 01
Second quarter 2022 earnings released: kr0.31 loss per share (vs kr0.12 loss in 2Q 2021) Second quarter 2022 results: kr0.31 loss per share (down from kr0.12 loss in 2Q 2021). Net loss: kr15.8m (loss widened 156% from 2Q 2021). Over the next year, revenue is forecast to grow 788%, compared to a 206% growth forecast for the Biotechs industry in Sweden. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has increased by 44% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • May 21
First quarter 2022 earnings: EPS and revenues miss analyst expectations First quarter 2022 results: kr0.21 loss per share (down from kr0.13 loss in 1Q 2021). Net loss: kr10.7m (loss widened 66% from 1Q 2021). Revenue missed analyst estimates by 85%. Earnings per share (EPS) also missed analyst estimates by 23%. Over the next year, revenue is forecast to grow 601%, compared to a 309% growth forecast for the industry in Sweden. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has increased by 60% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Apr 08
Full year 2021 earnings: EPS and revenues miss analyst expectations Full year 2021 results: kr0.59 loss per share (down from kr0.55 loss in FY 2020). Net loss: kr29.4m (loss widened 15% from FY 2020). Post-clinical trial products Approved (during full year): 1 Revenue missed analyst estimates by 85%. Earnings per share (EPS) also missed analyst estimates by 23%. Over the next year, revenue is forecast to grow 382%, compared to a 217% growth forecast for the pharmaceuticals industry in Sweden. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has increased by 65% per year, which means it is tracking significantly ahead of earnings growth. Breakeven Date Change • Feb 22
Forecast breakeven date pushed back to 2023 The analyst covering Intervacc previously expected the company to break even in 2022. New forecast suggests losses will reduce by 22% to 2022. The company is expected to make a profit of kr4.00m in 2023. Average annual earnings growth of 104% is required to achieve expected profit on schedule. Reported Earnings • Feb 19
Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind Full year 2021 results: kr0.59 loss per share (down from kr0.55 loss in FY 2020). Net loss: kr29.4m (loss widened 15% from FY 2020). Revenue missed analyst estimates by 85%. Earnings per share (EPS) exceeded analyst estimates by 23%. Over the next year, revenue is forecast to grow 914%, compared to a 216% growth forecast for the pharmaceuticals industry in Sweden. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has increased by 67% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Nov 12
Third quarter 2021 earnings released: kr0.17 loss per share (vs kr0.13 loss in 3Q 2020) Third quarter 2021 results: Net loss: kr8.32m (loss widened 30% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has increased by 107% per year, which means it is tracking significantly ahead of earnings growth. Reported Earnings • Sep 01
Second quarter 2021 earnings released: kr0.12 loss per share (vs kr0.13 loss in 2Q 2020) Second quarter 2021 results: Net loss: kr6.15m (loss widened 6.2% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has increased by 98% per year, which means it is tracking significantly ahead of earnings growth. Executive Departure • Jun 16
Independent Director Newton Aguiar has left the company On the 9th of June, Newton Aguiar's tenure as Independent Director ended. As of March 2021, Newton still personally held 2.85m shares (kr222m worth at the time). Newton is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 1.38 years, which is considered inexperienced in the Simply Wall St Risk Model. Reported Earnings • May 22
First quarter 2021 earnings released: kr0.13 loss per share (vs kr0.15 loss in 1Q 2020) First quarter 2021 results: Net loss: kr6.48m (loss widened 2.6% from 1Q 2020). Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has increased by 177% per year, which means it is tracking significantly ahead of earnings growth. Recent Insider Transactions • Apr 18
Independent Director recently sold kr29m worth of stock On the 13th of April, Newton Aguiar sold around 345k shares on-market at roughly kr85.00 per share. This was the largest sale by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.